Please login to the form below

Not currently logged in
Email:
Password:

Potenza

This page shows the latest Potenza news and features for those working in and with pharma, biotech and healthcare.

Astellas extends phase III programme for Rydapt rival gilteritinib

Astellas extends phase III programme for Rydapt rival gilteritinib

Oncology is a key priority for Astellas, and along with the Ganymed buy, it signed a wide-ranging immuno-oncology deal with Potenza Therapeutics last year, and followed it up with

Latest news

  • Astellas buys Ganymed to boost immuno-oncology pipeline Astellas buys Ganymed to boost immuno-oncology pipeline

    Last year it signed a wide-ranging immuno-oncology deal with Potenza Therapeutics and followed it up with a $300m licensing deal with Immunomic Therapeutics.

  • Astellas signs up to immuno-oncology deal Astellas signs up to immuno-oncology deal

    Under the immediate terms of the collaboration agreement, Potenza will lead drug discovery activities and deliver development candidates to Astellas. ... The new targets and pathways that Potenza is working on offer promise for continued expansion of

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics